![\"\"](\"https:\/\/sites.manchester.ac.uk\/mfig\/wp-content\/uploads\/sites\/267\/2021\/02\/Mike-Bromley-221x300.jpg\")
Dr Mike Bromley<\/p><\/div>\n
MFIG is delighted to announce the appointments of Dr Mike Bromley as Director and Prof David Denning as Deputy Director of MFIG.<\/strong><\/p>\n As a former co-director of MFIG, Mike is an internationally recognised leader in the study of drug resistance and drug discovery in human fungal pathogens. After his PhD, he started his research career at the antifungal drug discovery company F2G Ltd. During his 7 years at the company, Mike led the novel target discovery efforts and contributed to the identification of the mechanism of action of the antifungal drug series Olorofim. Since his appointment at Manchester, Mike has led large scale collaborative efforts to identify novel antifungals and is currently working on the development of two novel classes of antifungal drug. Mike also leads the Wellcome funded A. fumigatus<\/em> genome wide knockout initiative (COFUN) and has published extensively on novel mechanisms of antifungal drug resistance. He has successfully launched a number of commercial companies including Genon Laboratories Ltd, Syngenics Ltd and PiQ Laboratories Ltd.<\/p>\n Prof David Denning<\/p><\/div>\n David is an infectious diseases clinician with expertise in fungal diseases and founding Director of the National Aspergillosis Centre in Manchester (2009-2020). He has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. In addition to his university roles, he is Chief Executive of the Global Action Fund for Fungal Infections (www.GAFFI.org<\/a>). He co-chairs the alternate year Advances Against Aspergillosis and Mucormycosis meetings. He is a member of the SEARO Task Force on AMR. He has published extensively, primarily on Aspergillus<\/em> and aspergillosis and is the founder of 2 University spinout biotechnology companies \u2013 F2G Ltd and Myconostica Ltd.<\/p>\n Mike says<\/p>\n \u201cOver a billion people are afflicted with a fungal disease at any given moment and each year over 1.5 million people die. Multidrug-resistant fungi are currently sweeping the world causing significant impacts on health outcomes. We stand at a pivotal point in our battle against antifungal drug resistance. With a number of promising novel antifungals close to regulatory approval, it is critical that we understand how best to use these agents to reduce the emergence of resistance and so prolong their effectiveness. Working closely with our teams in the National Aspergillosis Center, The Mycology Reference Centre and collaborators across the globe our objectives are to improve the accuracy of infection diagnosis, understand the drivers of antifungal resistance, develop strategies to tackle the emergence of resistance and translate these solutions at pace with our clinical partners.\u201d<\/p>\n \u00a0<\/p>\n [\/et_pb_text][et_pb_post_nav _builder_version=”3.0.106″ in_same_term=”off” show_prev=”on” show_next=”on” prev_text=”Previous” next_text=”Next” locked=”on” parent_locked=”off” \/][et_pb_comments _builder_version=”3.0.106″ show_avatar=”on” show_reply=”on” show_count=”on” background_layout=”light” header_font_size_tablet=”51″ header_line_height_tablet=”2″ custom_button=”on” button_icon_placement=”right” button_text_color=”#ffffff” button_use_icon=”off” locked=”on” parent_locked=”off” button_text_size__hover_enabled=”off” button_text_size__hover=”null” button_one_text_size__hover_enabled=”off” button_one_text_size__hover=”null” button_two_text_size__hover_enabled=”off” button_two_text_size__hover=”null” button_text_color__hover_enabled=”off” button_text_color__hover=”null” button_one_text_color__hover_enabled=”off” button_one_text_color__hover=”null” button_two_text_color__hover_enabled=”off” button_two_text_color__hover=”null” button_border_width__hover_enabled=”off” button_border_width__hover=”null” button_one_border_width__hover_enabled=”off” button_one_border_width__hover=”null” button_two_border_width__hover_enabled=”off” button_two_border_width__hover=”null” button_border_color__hover_enabled=”off” button_border_color__hover=”null” button_one_border_color__hover_enabled=”off” button_one_border_color__hover=”null” button_two_border_color__hover_enabled=”off” button_two_border_color__hover=”null” button_border_radius__hover_enabled=”off” button_border_radius__hover=”null” button_one_border_radius__hover_enabled=”off” button_one_border_radius__hover=”null” button_two_border_radius__hover_enabled=”off” button_two_border_radius__hover=”null” button_letter_spacing__hover_enabled=”off” button_letter_spacing__hover=”null” button_one_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover=”null” button_two_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover=”null” button_bg_color__hover_enabled=”off” button_bg_color__hover=”null” button_one_bg_color__hover_enabled=”off” button_one_bg_color__hover=”null” button_two_bg_color__hover_enabled=”off” button_two_bg_color__hover=”null” \/][et_pb_text admin_label=”Related posts” _builder_version=”3.0.106″ background_layout=”light” locked=”on” parent_locked=”off”]<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_3″][et_pb_sidebar _builder_version=”3.0.106″ area=”sidebar-1″ orientation=”left” show_border=”off” background_layout=”light” locked=”on” \/][\/et_pb_column][\/et_pb_section][et_pb_section bb_built=”1″ admin_label=”Connect Title” custom_padding=”0px||0px|” _builder_version=”3.0.90″ background_color=”#1d1d1d” module_class=”footer-section” prev_background_color=”#ffffff” global_module=”380″][et_pb_row admin_label=”row” global_parent=”380″ locked=”off” allow_player_pause=”off” parallax=”off” parallax_method=”on” parallax_1=”off” parallax_method_1=”off” parallax_2=”off” parallax_method_2=”off” parallax_3=”off” parallax_method_3=”off” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” make_equal=”off” module_id=”footer-row” _builder_version=”3.0.89″][et_pb_column type=”1_3″][et_pb_text admin_label=”Contact Us Title” global_parent=”380″ background_layout=”dark” text_text_color=”#ffffff” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Contact Us” global_parent=”380″ text_text_color=”#aaaaaa” parent_locked=”off” background_layout=”light” text_orientation=”left” use_border_color=”off” module_class=”contact-us” background_position=”top_left” background_repeat=”repeat” background_size=”initial” _builder_version=”3.17.6″]<\/p>\n Mrs Carolyn Glynn (Centre Manager) [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Find Us Title” global_parent=”380″ background_layout=”dark” text_text_color=”#ffffff” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Address” global_parent=”380″ background_layout=”dark” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_id=”address” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n The University of Manchester [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Connect Title” global_parent=”380″ background_layout=”dark” text_text_color=”#ffffff” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n [\/et_pb_text][et_pb_code admin_label=”Social Media” global_parent=”380″ parent_locked=”off” _builder_version=”3.17.6″]<\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/ul>\n [\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" MFIG is delighted to announce the appointments of Dr Mike Bromley as Director and Prof David Denning as Deputy Director of MFIG.As a former co-director of MFIG, Mike is an internationally recognised leader in the study of drug resistance and drug discovery in human fungal pathogens. After his PhD, he started his research career at […]<\/p>\n","protected":false},"author":59,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":" \u00a0<\/p>[caption id=\"attachment_1561\" align=\"alignright\" width=\"175\"] \u00a0<\/p> \u00a0<\/p>[caption id=\"attachment_1562\" align=\"alignleft\" width=\"136\"] \u00a0<\/p> \u00a0<\/p>","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-1558","post","type-post","status-publish","format-standard","hentry","category-recent-news"],"_links":{"self":[{"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/posts\/1558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/comments?post=1558"}],"version-history":[{"count":24,"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/posts\/1558\/revisions"}],"predecessor-version":[{"id":1586,"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/posts\/1558\/revisions\/1586"}],"wp:attachment":[{"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/media?parent=1558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/categories?post=1558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.manchester.ac.uk\/mfig\/wp-json\/wp\/v2\/tags?post=1558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/sites.manchester.ac.uk\/mfig\/wp-content\/uploads\/sites\/267\/2021\/02\/David-Denning-169x300.jpg\")
Related<\/h1>\n
Related posts:<\/h3>
ESCMID Postgraduate Education Course: Crash course on invasive fungal infections<\/h2><\/div><\/div><\/a>
MFIG's origins and mission<\/h2><\/div><\/div><\/a>
MFIG Graduation celebrations<\/h2><\/div><\/div><\/a><\/div>
Contact Us<\/h4>\n
Email:\u00a0carolyn.glynn@manchester.ac.uk<\/a>
Tel:\u00a0(+44) 0161 275 5482<\/a><\/p>\nFind Us<\/h4>\n
Oxford Rd
Manchester
M13 9PL
UK<\/a><\/p>\nConnect With Us<\/h4>\n
<\/p>\n
![\"Facebook](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-facebook-50.png\"){kind=icon}
<\/a><\/li>\n![\"Twitter](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-twitter-50.png\"){kind=icon}
<\/a><\/li>\n![\"YouTube](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-youtube-50.png\"){kind=icon}
<\/a><\/li>\n![\"Instagram](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-instagram-50.svg\"){kind=icon}
<\/a><\/li>\nMFIG is delighted to announce the appointments of Dr Mike Bromley as Director and Prof David Denning as Deputy Director of MFIG.<\/strong><\/h3>
Dr Mike Bromley[\/caption]As a former co-director of MFIG, Mike is an internationally recognised leader in the study of drug resistance and drug discovery in human fungal pathogens. After his PhD, he started his research career at the antifungal drug discovery company F2G Ltd. During his 7 years at the company, Mike led the novel target discovery efforts and contributed to the identification of the mechanism of action of the antifungal drug series Olorofim. Since his appointment at Manchester, Mike has led large scale collaborative efforts to identify novel antifungals and is currently working on the development of two novel classes of antifungal drug. Mike also leads the Wellcome funded A. fumigatus<\/em> genome wide knockout initiative (COFUN) and has published extensively on novel mechanisms of antifungal drug resistance. He has successfully launched a number of commercial companies including Genon Laboratories Ltd, Syngenics Ltd and PiQ Laboratories Ltd.<\/h6>
Prof David Denning[\/caption]David is an infectious diseases clinician with expertise in fungal diseases and founding Director of the National Aspergillosis Centre in Manchester (2009-2020). He has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. In addition to his university roles, he is Chief Executive of the Global Action Fund for Fungal Infections (www.GAFFI.org<\/a>). He co-chairs the alternate year Advances Against Aspergillosis and Mucormycosis meetings. He is a member of the SEARO Task Force on AMR. He has published extensively, primarily on Aspergillus<\/em> and aspergillosis and is the founder of 2 University spinout biotechnology companies \u2013 F2G Ltd and Myconostica Ltd.<\/h6>
Mike says<\/h6>
\u201cOver a billion people are afflicted with a fungal disease at any given moment and each year over 1.5 million people die. Multidrug-resistant fungi are currently sweeping the world causing significant impacts on health outcomes. We stand at a pivotal point in our battle against antifungal drug resistance. With a number of promising novel antifungals close to regulatory approval, it is critical that we understand how best to use these agents to reduce the emergence of resistance and so prolong their effectiveness. Working closely with our teams in the National Aspergillosis Center, The Mycology Reference Centre and collaborators across the globe our objectives are to improve the accuracy of infection diagnosis, understand the drivers of antifungal resistance, develop strategies to tackle the emergence of resistance and translate these solutions at pace with our clinical partners.\u201d<\/h6>
\u00a0<\/h6>